Tag Archives: Castrate-Resistant Prostate Cancer Market Size

Castrate-resistant prostate cancer (CRPC) represents the most aggressive form of prostate cancer, one that continues to progress despite androgen-deprivation therapy (ADT), which is the primary treatment for early-stage prostate cancer. The global market for CRPC therapies was valued at USD 11.19 billion in 2023 and is projected to reach USD …

Read More »